Long-term data show clinical remission and endoscopic response rates are maintained and even improve over time in patients with moderate to severe Crohn's disease, according to a new study.
. In the most conservative analysis, "you see a benefit the longer you follow the patients…We haven't seen this with many — if any — other compounds before."
Generally, "I think we all have the impression that the IL-23 inhibitors have good efficacy, probably even better than other compounds available," said Ferrante. "And, importantly, this is true without any increased adverse effects." Data for the population, after patients who received rescue treatment were imputed as nonresponders, showed Clinical Disease Activity Index clinical response of 84.9% at week 56 and 52.7% at week 152. CDAI clinical remission was 66.7% at week 56 and 47.2% at week 152 for this population.
In light of this issue, "the investigators have used the most stringent way of handling these patients, regarding all who drop out as instances of failure of the drug. This offers the most robust assessment of durability of response that may slightly underestimate the true long-term efficacy," said Raine.
Dr Ferrante has declare research grants from: AbbVie, Amgen, Biogen, EG, Janssen, Pfizer, Takeda, and Viatris;
Norge Siste Nytt, Norge Overskrifter
Similar News:Du kan også lese nyheter som ligner på denne som vi har samlet inn fra andre nyhetskilder.
Early drug treatment leads to better outcomes for Crohn’s diseaseAbout 80 per cent of people who received infliximab straight after diagnosis with the inflammatory bowel condition had controlled their symptoms after a year, compared with just 15 per cent of those following a standard regime
Les mer »
Mass Spectrometry in Clinical Research - Houston, Texas (US) job with Baylor College of Medicine (BCM)The Division of Surgical Oncology is seeking a highly qualified individual with a PhD and postdoctoral experience in mass spectrometry and experience with clinical projects. The Staff Scientist would work alongside Dr.
Les mer »
A new study reports results of a phase-3 clinical trial of xanomeline-trospium.A potential new antipsychotic medication with a different mechanism of action may help expand treatment options for people with schizophrenia.
Les mer »
Calls for Greater Transparency in Medical Science as Study Finds Nonpublication of Clinical Trial ResultsCampaigners for greater transparency in medical science have reiterated calls for more to be done to avoid 'medical research waste' after an investigation found that results from more than a fifth of clinical trials across five Nordic countries have never been made public.
Les mer »
First-Ever CRISPR-Based Therapy Approved for Sickle Cell DiseaseU.S. patients with sickle cell disease now have a novel treatment option: the first-ever CRISPR-based therapy.for use in patients age 12 years and older. In addition to offering hope of relief for people with severe forms of the painful blood disorder, the treatment, called Casgevy, is the world’s first to genetically tweak cells using theAnother gene therapy for sickle cell disease, called Lyfgenia and developed by biotech company bluebird bio, based in Somerville, Mass., was also approved December 8. Getting a green light for the first CRISPR-based medicine is exciting, says David Altshuler, chief scientific officer at Boston-based Vertex Pharmaceuticals, which developed the drug in a joint venture with CRISPR Therapeutics, a company in Cambridge, Mass. But the fact that the drug fills an unmet need for underserved patients is “more compelling to me, personally, than the fact that it’s CRISPR.” , most of them Black or Latino, have sickle cell disease. It is caused by a genetic defect in hemoglobin, the oxygen-carrying protein in red blood cells
Les mer »
Alzheimer's Disease Symptoms & Early DiagnosisMemory loss and confusion can be signs of normal aging, but also warning signs of Alzheimer's disease. The early stages of Alzheimer's disease can affect problem solving, vision, and more.
Les mer »